The Crosstalk between Acetylation and Phosphorylation: Emerging New Roles for HDAC Inhibitors in the Heart
1
Cellular and Molecular Biology, University of Nevada, Reno, NV 89557, USA
2
Department of Nutrition, University of Nevada, Reno, NV 89557, USA
3
Center for Cardiovascular Research, University of Nevada, Reno, NV 89557, USA
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(1), 102; https://doi.org/10.3390/ijms20010102
Received: 18 November 2018
/
Revised: 20 December 2018
/
Accepted: 22 December 2018
/
Published: 28 December 2018
(This article belongs to the Special Issue Histone Deacetylase Inhibitors in Health and Disease)
Approximately five million United States (U.S.) adults are diagnosed with heart failure (HF), with eight million U.S. adults projected to suffer from HF by 2030. With five-year mortality rates following HF diagnosis approximating 50%, novel therapeutic treatments are needed for HF patients. Pre-clinical animal models of HF have highlighted histone deacetylase (HDAC) inhibitors as efficacious therapeutics that can stop and potentially reverse cardiac remodeling and dysfunction linked with HF development. HDACs remove acetyl groups from nucleosomal histones, altering DNA-histone protein electrostatic interactions in the regulation of gene expression. However, HDACs also remove acetyl groups from non-histone proteins in various tissues. Changes in histone and non-histone protein acetylation plays a key role in protein structure and function that can alter other post translational modifications (PTMs), including protein phosphorylation. Protein phosphorylation is a well described PTM that is important for cardiac signal transduction, protein activity and gene expression, yet the functional role for acetylation-phosphorylation cross-talk in the myocardium remains less clear. This review will focus on the regulation and function for acetylation-phosphorylation cross-talk in the heart, with a focus on the role for HDACs and HDAC inhibitors as regulators of acetyl-phosphorylation cross-talk in the control of cardiac function.
View Full-Text
Keywords:
HDACs; histone deacetylases; PTMs; post-translational modifications; acetylation; lysine acetylation; heart failure; cardiac dysfunction
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Habibian, J.; Ferguson, B.S. The Crosstalk between Acetylation and Phosphorylation: Emerging New Roles for HDAC Inhibitors in the Heart. Int. J. Mol. Sci. 2019, 20, 102. https://doi.org/10.3390/ijms20010102
AMA Style
Habibian J, Ferguson BS. The Crosstalk between Acetylation and Phosphorylation: Emerging New Roles for HDAC Inhibitors in the Heart. International Journal of Molecular Sciences. 2019; 20(1):102. https://doi.org/10.3390/ijms20010102
Chicago/Turabian StyleHabibian, Justine, and Bradley S. Ferguson. 2019. "The Crosstalk between Acetylation and Phosphorylation: Emerging New Roles for HDAC Inhibitors in the Heart" International Journal of Molecular Sciences 20, no. 1: 102. https://doi.org/10.3390/ijms20010102
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
